Statistics for ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional
Total visits
| views | |
|---|---|
| ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional | 77 |
Total visits per month
| views | |
|---|---|
| January 2025 | 13 |
| February 2025 | 6 |
| March 2025 | 0 |
| April 2025 | 3 |
| May 2025 | 12 |
| June 2025 | 1 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| REVISION_RAPIDA_042_2021 | 53 |